Abbott Laboratories (ABT) fell 1.43% to close at $121.76 following the announcement of 10% tariffs on eight European nations, creating significant geopolitical headwinds for the healthcare sector.
- The tariffs, which are set to escalate to 25% by June 1, pose risks to Abbott’s margins, particularly within its Nutrition and Electrophysiology segments due to significant European supply chain exposure.
- Despite the headwinds, analysts maintain a "Moderate Buy" consensus rating with an average price target of $146.61, implying a potential 17% upside.
- Positive catalysts include recent innovations such as the Libre Assist AI (unveiled at CES 2026) and the scaling of the Lingo biowearable platform.